Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

An Open Label Study to Establish the Preferred Dose and to Assess Safety and Overall Response Rate of Avastin in Combination With Concomitant Thoracic Radiation and Chemotherapy (Cisplatin and Etoposide) in Locally Advanced Unresectable Non-Squamous Non-Small Cell Lung Cancer.

Next Previous
Trial Profile

An Open Label Study to Establish the Preferred Dose and to Assess Safety and Overall Response Rate of Avastin in Combination With Concomitant Thoracic Radiation and Chemotherapy (Cisplatin and Etoposide) in Locally Advanced Unresectable Non-Squamous Non-Small Cell Lung Cancer.

Status: Completed
Phase of Trial: Phase I

Latest Information Update: 15 May 2015

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Bevacizumab (Primary) ; Cisplatin; Etoposide
  • Indications Non-small cell lung cancer; Squamous cell cancer
  • Focus Adverse reactions
  • Sponsors Roche

Most Recent Events

  • 23 Feb 2010 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
  • 15 May 2009 Planned end date changed from 1 Oct 2010 to 1 Sep 2011 as reported by ClinicalTrials.gov.
  • 22 Oct 2008 New trial record.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top